← All indications
Epidermolysis Bullosa Dystrophica
Form of epidermolysis bullosa characterized by atrophy of blistered areas, severe scarring, and nail changes. It is most often present at birth or in early infancy and occurs in both autosomal dominant and recessive forms. All forms of dystrophic epidermolysis bullosa result from mutations in COLLAGEN TYPE VII, a major component fibrils of BASEMENT MEMBRANE and EPIDERMIS.
Drugs by status
Approved for this indication (1)
Phase 3 trials (3)
Phase 2 trials (16)
Other trials (1)
Organizations
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (24)
- Intrexon
- Aeglea Biotherapeutics
- FGK Clinical Research GmbH
- Holostem Terapie Avanzate s.r.l.
- ProQR Therapeutics
- Rheacell GmbH & Co. KG
- Daewoong Pharmaceutical Co. LTD.
- Healthpoint
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of London
- Paracelsus Medical University
- Universidad Autonoma de Madrid
- University of Salzburg
- University of Southern California
- Yonsei University
- Vanderbilt University
- University of Nice Sophia Antipolis
- CIBERER
- TICEBA GmbH
- Granzer Regulatory Consulting & Services
- Lenus Therapeutics, LLC
- Phoenix Tissue Repair, Inc.
- Universidad Carlos III Madrid
- DEBRA
Organization Involved with Phase 1 Indications (3)